Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly

Anticancer Res. 2017 Jun;37(6):3287-3290. doi: 10.21873/anticanres.11694.

Abstract

Aim: The number of very elderly patients with cancer is growing and requires particular attention. The role of organ-sparing irradiation in patients with bladder cancer aged ≥80 years was investigated.

Patients and methods: In 29 very elderly (≥80 years) patients irradiated for bladder cancer, 12 characteristics were analysed for survival: indication, gender, age, Karnofsky performance score (KPS), T-/N-category, tumour grade, pack years, smoking during irradiation, radiation dose, interruption of irradiation >5 days and concurrent chemotherapy.

Results: On univariate analysis, primary treatment (p=0.001), KPS >70 (p=0.026) and not smoking during radiotherapy (p<0.001) were associated with better survival. A strong trend for such association was observed for female gender (p=0.054), <40 pack years (p=0.064) and concurrent chemotherapy (p=0.061), and a trend for no interruption of irradiation (p=0.09). On multivariate analysis, primary treatment (p=0.006) and not smoking during radiotherapy (p=0.038) maintained significance.

Conclusion: Very elderly patients irradiated for bladder cancer may benefit from concurrent chemotherapy. Smoking during irradiation and interruptions of irradiation should be avoided.

Keywords: Very elderly patients; bladder cancer; organ preservation; radio-chemotherapy; radiotherapy.

MeSH terms

  • Age Factors
  • Aged, 80 and over
  • Chemoradiotherapy* / adverse effects
  • Chemoradiotherapy* / mortality
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Karnofsky Performance Status
  • Male
  • Multivariate Analysis
  • Neoplasm Grading
  • Neoplasm Recurrence, Local*
  • Proportional Hazards Models
  • Radiation Dosage*
  • Risk Factors
  • Smoking / adverse effects
  • Smoking / mortality
  • Time Factors
  • Treatment Outcome
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / radiotherapy*